Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
Tiragolumab (MTIG7192A) is an anti-human TIGIT (T cell immunoreceptor with Ig ITIM domain) antibody that potentially has anti-tumor activities through modulating the immune response to tumors (PMID: 29991503, PMID: 32576590).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Tiragolumab||RO7092284|RG6058|MTIG7192A||Immune Checkpoint Inhibitor 153 TIGIT Antibody 18||Tiragolumab (MTIG7192A) is an anti-human TIGIT (T cell immunoreceptor with Ig ITIM domain) antibody that potentially has anti-tumor activities through modulating the immune response to tumors (PMID: 29991503, PMID: 32576590).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05394337||Phase I||Tiragolumab Atezolizumab||Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma||Recruiting||USA||0|
|NCT02794571||Phase I||Atezolizumab + Tiragolumab Tiragolumab||Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors||Active, not recruiting||USA | FRA | ESP | CAN||3|
|NCT04045028||Phase I||Tiragolumab Daratumumab + Tiragolumab Rituximab + Tiragolumab||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma||Active, not recruiting||USA||1|